Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Diaz

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
The Lancet. Oncology|February 13, 2013
NICE guidance on ipilimumab for previously treated advanced melanomaRichard A Diaz, Raisa Sidhu, Janet Robertson, et al.
The Lancet. Respiratory Medicine|January 17, 2014
NICE guidance on omalizumab for severe asthmaRichard A Diaz, Zoe Charles, Elisabeth George, et al.
The Lancet. Neurology|October 7, 2014
Alemtuzumab for relapsing-remitting multiple sclerosisRichard A Diaz, Sally Doss, Martyn J Burke, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
The Lancet. Oncology|February 13, 2013
NICE guidance on ipilimumab for previously treated advanced melanomaRichard A Diaz, Raisa Sidhu, Janet Robertson, et al.
The Lancet. Respiratory Medicine|January 17, 2014
NICE guidance on omalizumab for severe asthmaRichard A Diaz, Zoe Charles, Elisabeth George, et al.
The Lancet. Neurology|October 7, 2014
Alemtuzumab for relapsing-remitting multiple sclerosisRichard A Diaz, Sally Doss, Martyn J Burke, et al.
Pageof 1